Medicamen Biotech Peer Comparison
NSE: MEDICAMEQ | BSE: 531146
₹257.00
₹-6.80
(-2.58%)
As on 28-Oct-2026 11:29IST
Market cap
₹373 Cr
Revenue (TTM)
₹203 Cr
P/E Ratio
34.5
P/B Ratio
1.3
Div. Yield
0.4 %
Edit
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
373 | 33,860 | 31,874 | 29,207 | 14,755 |
Revenue (₹ Cr) |
203 | 4,683 | 2,891 | 4,213 | 857 |
Net Profit (₹ Cr) |
10.04 | 552.34 | 546.30 | 190.80 | 187.49 |
Net Margin (%) |
4.87 | 11.55 | 18.23 | 4.49 | 21.32 |
RoE (%) |
3.93 | 14.93 | 23.03 | 9.45 | 20.58 |
Price to Earnings |
34.45 | 60.88 | 58.82 | 142.96 | 78.70 |
Price-To-Book |
1.30 | 8.23 | 12.20 | 7.72 | 14.65 |
Income Statement (₹ Cr)
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Operating Revenue
|
202.62 | 4,683.37 | 2,890.80 | 4,212.50 | 857.13 |
|
Total Income
|
206.13 | 4,783.78 | 2,995.90 | 4,248.00 | 879.41 |
|
Total Expenditure
|
183.32 | 3,704.62 | 2,053.10 | 3,379.70 | 495.19 |
|
EBITDA
|
19.30 | 978.75 | 837.70 | 832.80 | 361.94 |
|
Depreciation
|
7.20 | 246.41 | 171.60 | 330.60 | 96.06 |
|
EBIT
|
12.09 | 732.34 | 666.10 | 502.20 | 265.89 |
|
Interest
|
3.17 | 92.01 | 24.40 | 253.30 | 36.75 |
|
Other Income
|
3.51 | 100.41 | 105.10 | 35.50 | 22.28 |
|
Exceptional Items
|
0.00 | -20.61 | -30.10 | -11.20 | 0.00 |
|
Profit before Tax
|
12.43 | 720.14 | 716.70 | 273.20 | 251.42 |
|
Provision for Tax
|
2.38 | 167.80 | 170.40 | 82.40 | 63.93 |
|
Profit after Tax
|
10.04 | 552.34 | 546.30 | 190.80 | 187.49 |
Liabilities (₹ Cr)
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
275.55 | 3,961.57 | 2,508.20 | 2,247.40 | 957.15 |
|
Minority Interest
|
0.79 | 3.84 | -4.40 | 9.90 | 0.00 |
|
Non-Current Liabilities
|
8.52 | 1,293.60 | 154.00 | 3,961.30 | 426.03 |
|
Current Liabilities
|
87.92 | 627.13 | 450.70 | 1,238.90 | 123.87 |
|
Total Liabilities
|
371.99 | 5,905.00 | 3,139.97 | 7,690.70 | 1,507.05 |
Assets (₹ Cr)
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
92.79 | 3,128.95 | 1,176.30 | 5,416.90 | 737.24 |
|
Current Assets
|
223.73 | 1,674.92 | 1,566.60 | 937.40 | 321.90 |
|
Total Assets
|
371.99 | 5,905.00 | 3,139.97 | 7,690.70 | 1,507.05 |
|
Total Debt*
|
49.20 | 631.08 | 0.00 | 3,244.00 | 0.00 |
|
Net Current Assets
|
135.81 | 1,047.79 | 1,115.90 | -301.50 | 198.03 |
|
Contingent Liabilities
|
-- | 100.01 | 16.76 | 81.10 | 0.13 |
Cashflow (₹ Cr)
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-33.17 | 714.39 | 635.61 | 510.80 | 270.59 |
|
Cash Flow from Investing Activities
|
-3.04 | -1,089.11 | -421.86 | -1,451.70 | -174.22 |
|
Cash from Financing Activities
|
63.72 | 271.85 | -263.57 | 940.30 | -69.49 |
|
Net Cash Inflow / Outflow
|
27.50 | -102.87 | -49.83 | -0.60 | 26.88 |
Ratios
Profitability Ratios
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.00 | 19.38 | 29.56 | 11.51 | 30.28 |
|
ROE (%)
|
3.93 | 14.93 | 23.03 | 9.45 | 20.58 |
|
ROA (%)
|
3.00 | 10.35 | 18.64 | 2.83 | 13.49 |
|
EBIT Margin (%)
|
5.97 | 15.64 | 23.04 | 11.92 | 31.02 |
|
Net Margin (%)
|
4.87 | 11.55 | 18.23 | 4.49 | 21.32 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
24.66 | 21.27 | 14.29 | 30.90 | 20.18 |
|
EBIT Growth (%)
|
52.44 | 0.94 | 15.64 | -16.88 | 26.22 |
|
Net Profit Growth (%)
|
37.69 | 3.43 | 5.38 | -52.81 | 24.27 |
|
EPS Growth (%)
|
8.37 | 2.70 | -30.51 | -42.60 | 23.44 |
|
Book Value Growth (%)
|
25.68 | 16.51 | 15.41 | 5.13 | 21.86 |
Valuation Ratios
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Price / Earnings
|
33.24 | 59.16 | 44.62 | 132.14 | 79.13 |
|
Price / Book Value
|
1.30 | 8.24 | 12.22 | 7.75 | 14.76 |
|
Dividend Yield (%)
|
0.38 | 0.04 | 1.08 | 0.00 | 0.14 |
|
EV/EBITDA
|
20.27 | 34.10 | 36.53 | 39.00 | 40.29 |
|
Market Cap (₹ Cr)
|
304.68 | 25,841.07 | 22,015.15 | 24,901.98 | 8,864.05 |
Solvency Ratios
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.02 | 0.15 | 0.00 | 1.19 | 0.00 |
|
Short term debt to equity ratio
|
0.15 | -- | -- | 0.15 | -- |
|
Current Ratio
|
2.54 | 2.67 | 3.48 | 0.76 | 2.60 |
|
Quick Ratio
|
1.75 | 2.54 | 3.38 | 0.68 | 2.56 |
|
Interest Coverage
|
4.92 | 8.83 | 30.37 | 2.08 | 7.84 |
Operating Efficiency Ratios
| Medicamen Biotech | Global Health | Dr. Lal Pathlabs | Krishna Institute | Vijaya Diagno | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
40.38 | 8.78 | 3.83 | 13.16 | 2.43 |
|
Asset Turnover
|
0.61 | 0.88 | 0.99 | 0.62 | 0.62 |
|
Receivable days
|
139.09 | 29.09 | 13.13 | 44.38 | 7.98 |
|
Inventory Days
|
122.01 | 6.05 | 5.28 | 7.52 | 2.20 |
|
Payable days
|
196.13 | 80.04 | 118.67 | 133.54 | 136.27 |
|
Cash Conversion Cycle
|
64.97 | -44.90 | -100.26 | -81.64 | -126.08 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
